SGT-501
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
Not Specified (Preclinical/Research)Active
Key Facts
Indication
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
Phase
Not Specified (Preclinical/Research)
Status
Active
Company
About Solid Biosciences
Solid Biosciences is a patient-centric, publicly traded biotech company dedicated to advancing a portfolio of gene therapy candidates for devastating rare diseases. Founded by those directly impacted by Duchenne muscular dystrophy, its mission is to improve patients' daily lives by uniting expertise in science, technology, and care. The company is advancing multiple programs in neuromuscular and cardiac diseases while developing enabling platform technologies to impact gene therapy delivery broadly. Solid emphasizes collaboration with stakeholders across industry, academia, and patient communities to accelerate the development of meaningful therapies.
View full company profile